Grifols has introduced its direct-to-consumer programme, AlphaID At Home Genetic Health Risk Service (AlphaID At Home), in the US.
The new programme will help screen for the genetic risk of alpha1-antitrypsin deficiency (alpha-1), which is also called genetic chronic obstructive pulmonary disease.
In November 2022, the US Food and Drug Administration (FDA) approved AlphaID At Home for direct-to-consumer use.
The test can screen for the most prevalently reported genetic mutations linked to alpha-1, including the S, Z, F and I alleles, as well as rare and null alleles.
It utilises the same precise genotyping test manufactured by the company and provided to physicians worldwide since 2018 for alpha-1 screening.
Grifols Diagnostic president Antonio Martínez said: “Given the fact that it can take several years until a patient with alpha-1 is properly diagnosed, AlphaID At Home can indicate someone’s risk for alpha-1 in a matter of weeks.”
AlphaID At Home is now accessible for ordering in the US at no cost via a secure online portal that complies with HIPAA standards.
After receiving the at-home screening kit, individuals can easily collect their saliva sample and send it to a laboratory adhering to the Clinical Laboratory Improvement Amendments standards for further processing.
Individuals can access their genetic results through a secure online portal after a few weeks.
Alpha-1 Foundation president and CEO Scott Santarella said: “We wholeheartedly support initiatives and innovations that contribute to the diagnosis of alpha-1. As leaders in alpha-1 testing, Grifols is doubling down on its commitment to the alpha-1 community by making it easier and more efficient to get diagnosed.”
<!-- GPT AdSlot 3 för annonsenheten 'Verdict/Verdict_In_Article' ### Storlek: [[670,220 XNUMX]] -- !-- Avsluta AdSlot 3 -->- SEO-drivet innehåll och PR-distribution. Bli förstärkt idag.
- PlatoAiStream. Web3 Data Intelligence. Kunskap förstärkt. Tillgång här.
- Minting the Future med Adryenn Ashley. Tillgång här.
- Köp och sälj aktier i PRE-IPO-företag med PREIPO®. Tillgång här.
- Källa: https://www.medicaldevice-network.com/news/grifols-alphaid-at-home-programme/
- : har
- :är
- 2018
- 2022
- 220
- a
- tillgång
- tillgänglig
- Ad
- administrering
- Efter
- också
- tillägg
- och
- godkänd
- AS
- At
- by
- kallas
- KAN
- Cancer
- VD
- Klinisk
- samla
- engagemang
- samfundet
- företag
- bidra
- Pris
- kredit
- Sjukdom
- fördubbling
- ner
- drog
- lättare
- lätt
- effektiv
- änden
- Faktum
- FDA
- få
- livsmedelsproduktion
- Food and Drug Administration
- Food and Drug Administration (FDA)
- För
- fundament
- ytterligare
- skaffa sig
- Hälsa
- hjälpa
- Hem
- HTTPS
- i
- förbättring
- in
- Inklusive
- indikerar
- individer
- initiativ
- innovationer
- Institute
- IT
- DESS
- jpg
- utrustning
- laboratorium
- ledare
- kopplade
- Framställning
- tillverkad
- Materia
- mer
- mer effektiv
- mest
- nationell
- Nya
- Nej
- November
- nu
- of
- on
- nätet
- ut
- Patienten
- plato
- Platon Data Intelligence
- PlatonData
- Portal
- exakt
- VD
- bearbetning
- programmet
- ordentligt
- förutsatt
- SÄLLSYNT
- mottagande
- Rapporterad
- Resultat
- Risk
- rullar
- s
- Nämnda
- Saliv
- Samma
- screen
- screening
- säkra
- sända
- service
- flera
- Dela
- eftersom
- Storlek
- standarder
- stödja
- Ta
- testa
- Testning
- den där
- Smakämnen
- deras
- detta
- Genom
- till
- enhet
- Unsplash
- tills
- us
- användning
- via
- veckor
- VÄL
- som
- helhjärtat
- kommer
- med
- inom hela sverige
- år
- zephyrnet